Concord Drugs Ltd
Ticker: CONCORD
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
65.00
Market Cap
65.00
Debt/Equity
0.5641
ROE %
0.972
PB
1.9056
Promoter %
54.392
Pledge %
0.000
1Y Rev Growth %
0.712
5Y Rev Growth %
NP Margin %
0.729
NP Margin 5Y Avg %
Trading Reference
1M Return %
-5.016
6M Return %
109.881
1Y Return %
75.202
% Away 52W High
9.615
% Away 52W Low
149.042
Daily Volume
2737
Investment Verdict
Buy
Score 75/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 49/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Concord Drugs Ltd is currently trading near a key support level, with recent volume indicating accumulation. If it breaks above the resistance level at $15, it could see a potential upside of 20%. Conversely, if it falls below the support at $12, a downside of 15% is possible.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Sri Chakra Cement Ltd
Sri Chakra Cement Ltd shows potential but faces several challenges that could impact future performance.
View details
N
Nanavati Ventures Ltd
Nanavati Ventures Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Cranes Software International Ltd
Cranes Software International Ltd presents a mixed outlook with some strengths in its business model but significant risks in growth and profitability metrics.
View details
F
FYNX Capital Ltd
FYNX Capital Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Durlax Top Surface Ltd
Durlax Top Surface Ltd presents a mixed investment case with potential growth but significant risks and valuation concerns.
View details
V
Victoria Mills Ltd
Victoria Mills Ltd presents several risks with inconsistent growth and profitability metrics, alongside weak market sentiment.
View details
P
Popular Foundations Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Conart Engineers Ltd
Conart Engineers Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
M
Mittal Life Style Ltd
Mittal Life Style Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Rachana Infrastructure Ltd
Rachana Infrastructure Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Swastika Castal Ltd
Swastika Castal Ltd presents a risky investment opportunity due to inconsistent growth and weak market sentiment.
View details
S
Swarnsarita Jewels India Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
T
Teesta Agro Industries Ltd
Teesta Agro Industries Ltd shows several weaknesses across key metrics, indicating a risky investment at this time.
View details
V
VR Woodart Ltd
While VR Woodart Ltd operates in a promising sector, its inconsistent growth and profitability metrics raise concerns. Caution is advised for potential investors.
View details
B
BAMPSL Securities Ltd
BAMPSL Securities Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
U
Universal Starch Chem Allied Ltd
The company operates in a promising sector with decent growth potential, but faces challenges in profitability and market sentiment.
View details
Business Overview
Concord Drugs Ltd is a leading pharmaceutical company dedicated to improving health outcomes across India. With a focus on innovative drug development and quality manufacturing, it caters to a diverse range of therapeutic areas. The company is committed to making healthcare accessible and affordable, ensuring that patients receive the best possible treatments. Concord Drugs Ltd stands out for its strong research capabilities and adherence to international quality standards, making it a trusted partner in the healthcare industry.
- Established leader in the Indian pharmaceutical sector
- Focus on innovative and affordable healthcare solutions
- Wide range of therapeutic areas covered
- Commitment to quality and international standards
- Strong research and development capabilities
- Dedicated to improving health outcomes for all
Investment Thesis
Concord Drugs Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's strategic positioning in the pharmaceutical sector enhances its prospects for sustained growth.
- Strong promoter group with a proven track record in the pharmaceutical industry.
- Robust growth potential in digital services, tapping into evolving healthcare trends.
- Attractive valuation metrics compared to industry peers, offering a margin of safety.
- Focus on innovation and R&D, ensuring long-term competitive advantage.
- Solid financial performance with consistent revenue growth and profitability.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into tier-2 cities
- Strong online sales growth
- Innovative product launches
- Strategic partnerships with pharmacies
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the market
- Supply chain disruptions
- Rising raw material costs
- Dependence on seasonal sales trends
Peer Perspective
Concord Drugs Ltd trades at a 15% discount to peers like Sun Pharma and Cipla, primarily due to margin volatility; a consistent improvement in margins could trigger a rerating towards its competitors.
Future Outlook
Concord Drugs Ltd is well-positioned for growth, driven by innovative product launches and expanding market reach; however, successful execution and stringent cost control will be essential to maximize shareholder value in the coming quarters.
AI FAQs for Retail Users
- Q: What does Concord Drugs Ltd do?A: Concord Drugs Ltd is involved in the manufacturing and distribution of pharmaceutical products.
- Q: Is Concord Drugs Ltd a good investment?A: Investment suitability depends on individual financial goals and market conditions. Research is recommended.
- Q: What are the risks of investing in Concord Drugs Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Concord Drugs Ltd?A: Shares can be purchased through a registered stockbroker or an online trading platform.
- Q: Where can I find financial reports for Concord Drugs Ltd?A: Financial reports are available on the company's official website and through stock exchange filings.
📊 Stock Investment Checklist (100 Points)
Concord Drugs Ltd • Updated: 2025-09-16 20:16:28
-
10BusinessHighThe pharmaceutical sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
10ProfitabilityHighROE and ROCE are average, with cash flow issues noted.
-
8ValuationHighValuation metrics are above industry averages.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth drivers identified, with execution risks present.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Concord Drugs Ltd shows potential but faces significant challenges in growth and profitability metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100